

# THE SCHEIE LOOKING GLASS

Volume 2, Number 1

Winter, 2001

## INSIDE THIS ISSUE:

- Faculty Awards & News 2
- Cosmetic Eye Surgery 3
- New Faculty 4
- SEI Faculty 5
- Diabetic Retinopathy 6
- Jeffrey W. Berger 7/8
- 127th Meeting Program 9/10
- Alumni News 11
- Lectures & Seminars 12



## SEI RECOGNIZED BY NIH & BY LEADERS IN OPHTHALMOLOGY

For the second consecutive year, Scheie Eye Institute ranks in the **Top 3** among all departments of ophthalmology in the U.S. in research funding by the National Eye Institute. This year our department's total number of individual grant awards increased from 18 to 22.

In the 2000 "Ophthalmology Times" Survey of all department chairs and residency program directors across the U.S., Scheie Eye Institute at Penn ranked among the **Top 10 best research programs and Top 10 best clinical (patient care) programs.**

We are proud of the accomplishments of our faculty in garnering research support from the National Eye Institute and we likewise are grateful for the recognition of our peers.

## BLOOD FLOW STUDIES AIM TO PREVENT VISION LOSS

### Ann Sacks

Americans are familiar with the consequences of fat-clogged arteries to the heart and brain. Blocked coronary arteries cause heart attack and blocked carotid arteries cause stroke by depriving vital organs of oxygen, without which, the organ stops functioning. But few of us give a second thought as to how blood flow through the retina can affect our vision. In fact, diminished blood flow or sudden increase in blood flow that results in a burst blood vessel (hemorrhage) can have a devastating effect on sight. Many of the most common diseases that affect the eye cause damage by adversely altering blood flow through the eye.

Macular degeneration and several conditions associated with retinal blood vessel closure exhibit a marked decrease in blood flow to the macula (the site of central vision), thereby robbing vision cells of life-giving nutrients. Glaucoma causes a large reduction in blood flow in the optic nerve long before patients start losing vision. Diabetic retinopathy, on the other hand, is characterized by increased blood flow as well as wide fluctuations in flow that eventually result in hemorrhages that can lead to visual impairment. Restoring adequate flow through the retina is a critical part of halting the deterioration of vision caused by these conditions.

The **Vivian Simkins Lasko Retinal Vascular Research Laboratory** at the Scheie Eye Institute is dedicated to research on vascular diseases in the



*Vivian Simkins Lasko Retinal Vascular Research Laboratory staff taking blood flow measurements in the eye of a normal control. From left: Cindu Jacob, Kelly Sui, Juan Grunwald, M.D., Director, Sharon Decker and Joan DuPont.*

eyes and to discovering ways to reverse their effects. Directed by **Juan Grunwald, M.D., Professor of Ophthalmology at the University of Pennsylvania**, the Laboratory has several grants from the National Eye Institute (NEI) and pharmaceutical companies to pursue studies on ocular blood flow in diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). Dr. Grunwald, along with Clinical Research Study Coordinator Joan DuPont, collaborates with other Scheie researchers including **Alexander Brucker, M.D., Albert Maguire, M.D., Jody Piltz-Seymour, M.D., Nicholas Volpe, M.D., Maureen Maguire, Ph.D.**, and others who are experts in these conditions.

Measurement of ocular blood flow is achieved by laser Doppler flowmetry, a state-of-the-art technique developed by physicist **Dr. Charles Riva**, while he was a researcher at Scheie in the 1980's

*Continued on page 2*

## RECENT FACULTY AWARDS

**Jean Bennett, M.D., Ph.D.**  
and **Michael Tolentino, M.D.**

Received Juvenile Diabetes Foundation Award, Gene Therapy for Diabetic Retinopathy as part of a Penn Program Project

**Samuel G. Jacobson, M.D., Ph.D.**

Received Research to Prevent Blindness Senior Scientist Award in December 2000

**Monte D. Mills, M.D.**

Named Mabel E. Leslie Endowed Chair in Pediatric Ophthalmology at The Children's Hospital of Philadelphia July 1, 2000

**Richard A. Stone, M.D.**

Received Research to Prevent Blindness Physician-Scientist Award in December 2000

**Michael Tolentino, M.D.**

Received the AOS-Knapp Fellowship in May 2000

**Edward Pugh, Ph.D.**

Appointed Chair of the Conference on the Biology and Chemistry of Vision, June 23-28, 2001. To register, visit the website <http://www.faseb.org> and for the program, visit <http://retina.anatomy.upenn.edu/faseb/>

### PUBLICATIONS COMMITTEE

**STUART L. FINE, M.D.**

*Chairman, Director and Editor*

**CHERYL ATKINS-LUBINSKI**

*Vice Chair and  
Chief Operating Officer*

**FRANCIS J. MANNING, M.D.**

*President of the Alumni Association*

**MARILYN KURLAND-COLUCCI**

*Special Assistant*

**SUE HESS**

*Director of Educational Activities*

**ANN SACKS**

*Director of Development and  
Alumni Relations*

**FRANCES MANNING SMITH**

*Senior Major Gifts Officer,  
Medical Center Development*

**MICHELE SZKOLNICKI, M.S., R.N.**

*Director of Network Administration  
and Clinical Resource Development*

Photography by  
Bill Nyberg and Jim Berger

### Blood Flow Studies Aim to Prevent Vision Loss . . . Continued from page 1



*Dr. Jody R. Piltz-Seymour at the slit lamp.*

and 1990's. As the patient sits comfortably in front of a special camera, the measurement is obtained by shining a very weak laser onto the back of the eye. From the light reflected back to the camera, the instrument can assess the volume, velocity and flow of blood through the retina, choroid and optic nerve. The measurement is painless, non-invasive and harmless. Once a baseline flow has been established, researchers can measure the effects of different treatments on blood flow or can follow the disease process by tracking the measurement over time.

In a study on age-related macular degeneration, Dr. Grunwald is testing his theory that drusen (the white spots seen in the back of the eye as precursors to loss of vision in AMD) collect in the back of the eye in part because of poor circulation of the choroid, a vascular tissue that nourishes the retina. Improvement in blood flow obtained by pharmacologic means or perhaps by laser therapy could lead to the disappearance of drusen. Decreasing the extent of drusen may decrease the risk

of the late and vision-threatening complications of AMD.

Another project being conducted at the laboratory is investigating whether Viagra, a potent dilator of blood vessels, may improve the choroidal circulation. Dr.


Grunwald was the first to show that choroidal blood flow in AMD decreases much more rapidly than can be attributed to normal aging. In a research project sponsored by NEI, Dr. Grunwald is testing whether measurements of decreased choroidal blood flow in patients with AMD may help predict which patients will develop visual impairment.

**Dr. Grunwald** and **Dr. Piltz** have also found that the circulation of the optic nerve is markedly reduced in glaucoma, a disease in which vision is lost because the nerve fibers of the optic nerve are damaged. This decrease in optic nerve blood flow occurs long before the patient starts losing vision, providing an opportunity to treat before vision loss is irreversible.

In diabetic retinopathy, blood flow is increased and the ability of the retina to regulate its blood flow is grossly abnormal. High blood sugars present in diabetic patients impair the regulation of blood flow in the eye. This lack of regulatory

capacity is important because it renders the retina more vulnerable to stress situations such as those produced, for example, by an increase in blood pressure in the tiny vessels of the retina. In people with diabetes, the lack of regulation can lead to burst vessels resulting in loss of vision. In order to gauge the eye's ability to regulate blood flow, the Laboratory performs "stress" tests on the eye. One of these stress tests consists in asking subjects to breathe pure oxygen. In normal subjects, breathing pure oxygen reduces retinal blood flow by 60%. As diabetes progresses, this response is blunted. Interestingly, laser treatment returns the response to normal by a mechanism that is not clearly understood.

In addition to the study of the effects of disease states on ocular blood flow, the Laboratory also studies the effects of medications on retinal blood flow. People over the age of 60 with healthy eyes are needed as controls for our AMD and glaucoma studies. Anyone interested should call Joan DuPont at (215) 662-8038.



*Macula with large drusen.*

## RECONSTRUCTIVE EXPERTISE IMPROVES COSMETIC OUTCOME

*Described by a patient as “an angel with butterfly fingers,” Dr. Roberta E. Gausas combines her reconstructive expertise with cosmetic surgery.*

“The eyes are the first thing to go.” This lament has brought many aging baby-boomers to visit a cosmetic surgeon. Since the eyelid skin is so fine and delicate, the first signs of aging frequently show up here as crow’s feet, puffiness and ptosis (droopy eyelids). However, what often makes a patient decide to have a procedure done are the comments of others describing the patient as looking fatigued. Cosmetic eyelid surgery can help reverse the appearance of baggy eyelids and return the patient to a rested, healthy, and younger look.

As **Director of the Oculoplastics and Orbital Surgery Service at the Scheie Eye Institute, Dr. Roberta E. Gausas** brings a special expertise to the art of eyelid surgery. After completing her residency at the University of Wisconsin at Madison, she continued her training there as a fellow in Ophthalmic Plastic and Reconstructive Surgery. She then completed a second fellowship in Orbital Disease and Surgery at Moorfields Eye Hospital in London.

In addition to cosmetic eye surgery, one of Dr. Gausas’ main interests is the treatment of orbital tumors. This interest allows her to collaborate frequently with colleagues in otolaryngology and neurosurgery for complex cases requiring a multidisciplinary approach. “These cases are both challenging and exciting because we have the goal to treat the disease and also to preserve the function of the eye and maintain the best possible cosmetic outcome for the patient,” said Dr. Gausas.



*Dr. Roberta Gausas performing a blepharoplasty (eyelid surgery) to correct baggy lids.*



*Dr. Roberta Gausas examining patient following recent ptosis surgery.*

“What makes my practice so gratifying is being able to treat patients for both reconstructive as well as cosmetic concerns.” It is this combination of reconstructive expertise and appreciation of the aesthetics of the human face that made Dr. Gausas one of the “Top Docs for Women” in the May 2000 issue of “Philadelphia Magazine.” But it is the accolades of patients like Mrs. Florence Fink who described Dr. Gausas as “an

angel with butterfly fingers” that truly demonstrate her talent.


In addition to her surgical practice and involvement in resident training, Dr. Gausas pursues research in orbital anatomy. Her work in identifying previously unknown orbital lymphatics was recognized with a special award from the American Society of Ophthalmic Plastic and Reconstructive Surgery in 1999.

## SEI WELCOMES NEW FACULTY

**Michael Tolentino, M.D.** was educated at Brown University and the University of Massachusetts Medical School. Following two years of laboratory research with Drs. Judah Folkman and Tony Adamis at Children's Hospital, Boston, Dr. Tolentino completed a residency at the Massachusetts Eye and Ear Infirmary where he continued to conduct research in the area of angiogenesis and angioinhibition. He has now completed a vitreoretinal fellowship at the Scheie Eye Institute and will commence clinical practice as a member of the Retina Service. In addition, he will be a scientist at the F.M. Kirby Center for Molecular Ophthalmology and continue his research in angiogenesis and angioinhibition.



**Jeffrey P. Wick, M.D.** was educated at Southwestern Medical School in Dallas and completed his residency at the University of Colorado in Denver. After two years of a high volume surgical practice in Laramie, Wyoming, Jeff realized that he missed the intellectual stimulation of an academic community. Accordingly, he returned to academe at the University of Utah and obtained a Masters degree in medical informatics. Dr. Wick joined the full-time faculty at Scheie Eye Institute in January 2001 where he will practice comprehensive ophthalmology and attend resident outpatient clinics and surgery at the VA and at Scheie Eye Institute. He also will help us implement an electronic medical record for the Institute in its various practice venues.



**Terri Young, M.D.** was educated at Harvard Medical School and completed her residency at the University of Illinois Eye and Ear Infirmary. Following a fellowship in pediatric ophthalmology at the Children's Hospital of Philadelphia, she returned to Boston for a full-time faculty position at the Children's Hospital. At Children's she was involved in patient care and also began her research career in the genetics of refractive errors. Several years later she was lured to the University of Minnesota where she remained on the faculty until September 2000 when she joined the full-time faculty at Penn. Dr. Young is an Associate Professor of Ophthalmology and Director of the Ophthalmic Genetics Disorders Clinic at CHOP.



## SPECIALTIES AND SERVICES

**Applied Ophthalmic Neurobiology Laboratory**  
Patricia Grimes, Ph.D.  
Alan Laties, M.D.  
Richard Stone, M.D.

**Center for Preventive Ophthalmology and Biostatistics**  
Judy Alexander, B.A.  
Mary Brightwell-Arnold, B.A.  
Maureen G. Maguire, Ph.D.  
Ellen Peskin, M.A.

**Center for Hereditary Retinal Degenerations**  
Artur Cideciyan, Ph.D.  
Samuel G. Jacobson, M.D., Ph.D.

**Comprehensive Ophthalmology**  
David M. Kozart, M.D.  
Mina Massaro-Giordano, M.D.  
Charles W. Nichols, M.D.  
Jane Portnoy, M.D.  
Anna Singh, M.D.  
Nasreen Syed, M.D.  
Jeffrey P. Wick, M.D.

**Contact Lenses**  
Debbie Dana  
Diane Heistand  
Cynthia Silvestri  
Fran Ward

**Cornea/External Diseases/ Refractive Surgery**  
Mina Massaro-Giordano, M.D.  
Stephen E. Orlin, M.D.  
Michael Sulewski, M.D.

**F.M. Kirby Center for Molecular Ophthalmology**  
Jean Bennett, M.D., Ph.D.  
Joshua Dunaief, M.D., Ph.D.  
Edward Pugh, Ph.D.  
Eric Pierce, M.D., Ph.D.  
Dwight E. Stambolian, M.D., Ph.D.  
Michael Tolentino, M.D.

**Genetics**  
Dwight E. Stambolian, M.D., Ph.D.

**Glaucoma**  
Evan B. Dreyer, M.D., Ph.D.  
Jody R. Piltz-Seymour, M.D.  
Anna Singh, M.D.  
Richard A. Stone, M.D.

**Glaucoma Research and Neuroprotection Laboratory**  
Alan M. Laties, M.D.

**Low Vision Research and Rehabilitation Center**  
Janet DeBerry Steinberg, O.D.

**Medical Retina**  
Alexander J. Brucker, M.D.  
Joshua Dunaief, M.D., Ph.D.  
Stuart L. Fine, M.D.  
Juan E. Grunwald, M.D.  
Albert M. Maguire, M.D.  
Michael Tolentino, M.D.

**Medical Therapies Initiative**  
Alan Laties, M.D.  
Rong Wen, M.D., Ph.D.

**Motility/Strabismus (Adult)**  
Nicholas J. Volpe, M.D.

**Neuro-Ophthalmology**  
Laura Balcer, M.D.  
Steven L. Galetta, M.D.  
Grant Liu, M.D.  
Nicholas J. Volpe, M.D.

**Ocular Vascular Research Laboratory**  
Joan Dupont  
Juan Grunwald, M.D.  
Charles Riva, D.Sc. (Adjunct)

**Oculoplastics & Orbital Disease & Surgery**  
Roberta E. Gausas, M.D.  
James A. Katowitz, M.D.

**Optical Shop**  
Patrick O'Brien  
Anita Taylor

**Pathology**  
William C. Frayer, M.D.  
Nasreen Syed, M.D.

**Pediatric Oculoplastic Surgery**  
James A. Katowitz, M.D.

**Pediatric Ophthalmology**  
Jane Edmond, M.D.  
Brian Forbes, M.D., Ph.D.  
Ellie Francis, O.D., Ph.D.  
Monte Mills, M.D.  
Eric Pierce, M.D., Ph.D.  
Graham E. Quinn, M.D.  
Terri Young, M.D.

**Photography**  
Jim Berger  
Cheryl Devine  
Deborah Elkins  
William Nyberg  
Laurel Weeney

**Retina & Vitreous Surgery**  
Alexander Brucker, M.D.  
Albert M. Maguire, M.D.  
Michael Tolentino, M.D.

**Retinal Degeneration**  
Histology Laboratory  
Ann H. Milam, Ph.D.


**Ultrasound**  
Kym Gendron

**Uveitis**  
Nasreen Syed, M.D.

**Development**  
Ann Sacks

**Education Coordinator**  
Sue Hess

# Scheie Eye Institute Faculty



Stuart L. Fine, M.D.  
Chairman and Director



Laura Balcer, M.D.  
Neuro-Ophthalmology  
Epidemiology



Jean Bennett, M.D., Ph.D.  
Retinal Degeneration  
Genetics Research



Jeffrey W. Berger, M.D., Ph.D.  
Retina & Vitreous  
Computer Vision Lab



Alexander J. Brucker, M.D.  
Retina & Vitreous



Artur V. Cideciyan, Ph.D.  
Retina Research



Evan B. Dreyer, M.D., Ph.D.  
Glaucoma



Joshua Dunaief, M.D., Ph.D.  
Medical Retina  
Retina Research



Jane Edmond, M.D.  
Pediatric Ophthalmology



Brian Forbes, M.D., Ph.D.  
Pediatric Ophthalmology



Ellie Francis, O.D., Ph.D.  
Pediatric Optometry



William C. Frayer, M.D.  
Pathology



Steven L. Galetta, M.D.  
Neuro-Ophthalmology



Roberta E. Gausas, M.D.  
Oculoplastics & Orbital  
Disease & Surgery




Juan E. Grunwald, M.D.  
Medical Retina  
Retina Research



Samuel G. Jacobson, M.D., Ph.D.  
Hereditary Retinal  
Degeneration



James A. Katowitz, M.D.  
Pediatric Oculoplastic  
Surgery



David M. Kozart, M.D.  
Vice Chairman, Administration  
Comprehensive Ophthalmology



Alan M. Latties, M.D.  
Retinal Degeneration  
Research



Grant T. Liu, M.D.  
Neuro-Ophthalmology



Albert M. Maguire, M.D.  
Retina & Vitreous  
Retinal Degeneration Research



Maureen G. Maguire, Ph.D.  
Biostatistics  
Epidemiology



Mina Massaro-Giordano, M.D.  
Comprehensive Ophthalmology  
Refractive Surgery



Ann H. Milam, Ph.D.  
Retina Research



Monte Mills, M.D.  
Pediatric Ophthalmology



Charles W. Nichols, M.D.  
Comprehensive Ophthalmology



Stephen E. Orlin, M.D.  
Cornea/External Diseases/  
Refractive Surgery



Eric Pierce, M.D., Ph.D.  
Pediatric Ophthalmology  
Genetics Research



Jody R. Piltz-Seymour, M.D.  
Glaucoma  
Glaucoma Research



Jane Portnoy, M.D.  
Comprehensive Ophthalmology



Edward N. Pugh, Ph.D.  
Retina Research



Graham E. Quinn, M.D.  
Pediatric Ophthalmology



Anna Singh, M.D.  
Comprehensive Ophthalmology  
Glaucoma



Dwight E. Stambolian, M.D., Ph.D.  
Genetics



Janet DeBrey Steinberg, O.D.  
Low Vision



Richard A. Stone, M.D.  
Vice Chairman, Research  
Glaucoma



Michael E. Sulewski, M.D.  
Cornea/External Diseases/  
Refractive Surgery



Nasreen A. Syed, M.D.  
Comprehensive Ophthalmology  
Pathology, Ureitis Research



Michael Tolentino, M.D.  
Retina & Vitreous  
Retina Research



Nicholas J. Volpe, M.D.  
Neuro-Ophthalmology  
Motility/Strabismus (Adult)



Rong Wen, M.D., Ph.D.  
Retina Research



Jeffrey P. Wick, M.D.  
Comprehensive Ophthalmology



Terri Young, M.D.  
Pediatric Ophthalmology

## PREVENTING BLINDNESS FROM DIABETIC RETINOPATHY

Researchers and physicians at Scheie Eye Institute are working to slow the progression of diabetic retinopathy and set the standards for the management of diabetes in the new millennium. Diabetic retinopathy is a progressive retinal disorder secondary to long-standing diabetes mellitus. Despite the fact that strict metabolic control and yearly eye exams have been shown to prevent or lessen vision loss due to diabetic retinopathy, from 12,000 to 24,000 people lose their sight each year due to diabetes. **Alexander J. Brucker, M.D., Professor of Ophthalmology at Scheie Eye Institute,** wants to change these statistics through research, education and community outreach. In order to get the message out, Dr. Brucker regularly lectures to colleagues and lay groups and he is the principal investigator on three clinical trials currently underway at Scheie.

### SANDOSTATIN AND PKC INHIBITORS

Sandostatin has been used for many years as a growth inhibitor for treatment of acromegaly. It was recently noted that acromegalic patients who were diabetic were less likely to develop the complications of diabetes including diabetic retinopathy and macular edema while using Sandostatin. Sandostatin is now being administered in a research study to patients with severe non-proliferative or early proliferative diabetic retinopathy. "We are excited

about this study and hope we have found a medication that may be able to prevent our patients from developing advanced stages of diabetic retinopathy," comments Dr. Brucker.

Another study involves the use of protein kinase C inhibitors (PKC) to also slow (if not stop) the progression of diabetic retinopathy and preserve vision. Vascular endothelial growth factor (VEGF) is believed to be a major contributing factor to the development of diabetic retinopathy. "Sandostatin and PKC inhibitors affect the production and effects of VEGF on vascular endothelial cells within the eye. Hopefully, their use will prevent progression of diabetic retinopathy" adds Dr. Brucker.

### ADVANCED DIABETES

A new clinical trial is being conducted for patients with vitreous hemorrhage. This late


stage of diabetic retinopathy causes patients to lose their vision due to hemorrhaging in the eye. The trial involves injecting a special enzyme into the eye that allows the absorption of the vitreous hemorrhage to occur at a very rapid rate. Hopefully, this would eliminate the need for pars plana vitrectomy surgery and permit, when necessary, additional laser surgery to prevent future hemorrhage. Recruitment for this study is ongoing.

### METABOLIC CONTROL

Dr. Brucker strongly advocates the benefits of strict metabolic control. "The risk of progression of diabetic retinopathy can be decreased by 76 percent in some instances with proper metabolic control. The landmark Diabetes Complication and Control Trial published in 1993 proved the benefits of strict metabolic

control compared to standard control. But despite overwhelming results, too many patients and physicians are unaware of or unwilling to follow the recommendations of this study," adds Dr. Brucker. A general goal should be to maintain Hemoglobin A1c levels in the normal range. This may require multiple insulin injections daily as well as fingersticks 4 or more times a day."

The ophthalmologists at Scheie are working with primary care physicians and endocrinologists for the recruitment and care of patients for these studies. To find out more about the research studies, including studies on photocoagulation and the effects of laser treatment on blood flow, or to refer a patient, please call the Scheie Eye Institute Retina Service at (215) 662-8675.



*Dr. Alexander (Sandy) Brucker examines a patient with diabetes.*

**On November 18, 2000, Dr. Brucker received the Lifetime Achievement Award from the Philadelphia Ophthalmic Club for his contributions to patient care, research, teaching and education in ophthalmology.**

## JEFFREY W. BERGER, M.D., PH.D. 1963-2001

*Scheie Eye  
Institute  
mourns the  
loss of  
Jeffrey W. Berger,  
M.D., Ph.D.*

*His passing is a  
tremendous loss  
to the multitude  
of people whose  
lives he touched  
and to untold  
thousands  
whose lives he  
would have  
touched had he  
lived a full life.*


Faculty and staff at the Scheie Eye Institute, hundreds of friends and family members, as well as patients and professional associates are mourning the loss of Jeffrey W. Berger, M.D., Ph.D. who died of cancer on January 25, 2001. Until three weeks before his death, Jeff was a vibrant and vital husband, father, friend, physician, surgeon, teacher, and scientist. He became ill

the first week of January, was diagnosed with gastric adenocarcinoma on Friday, January 12, and passed away on Thursday, January 25. His passing is a tremendous loss to the multitude of people whose lives he touched and to untold thousands whose lives he would have touched had he lived a full life.

And yet in a larger sense Jeff lived an extraordinarily full life that was compressed

into just 37 years. He was graduated in 1985 from Princeton with a bachelor of science degree in engineering and in 1992 obtained M.D. and Ph.D. degrees from the University of Pennsylvania. After a residency at the Massachusetts Eye and Ear Infirmary, he came to Scheie Eye Institute as a fellow in vitreoretinal diseases in 1996 and remained on the faculty

*Continued on page 8*



Jeffrey W. Berger, M.D., Ph.D. . . . *Continued from page 7*

from 1997 to 2001.

During his short tenure at Scheie/Penn, Jeff had an extraordinary number of accomplishments. He founded and directed the Computer Vision Laboratory which was funded in part by a Career Development Award from Research to Prevent Blindness, Inc. of New York and in part by the National Eye Institute through his Mentored Clinician-Scientist Award. Jeff also served as principal investigator of the Reading Center for the NEI-funded Complications of AMD Prevention Trial (CAPT). A third NEI grant had just received a favorable evaluation.

In addition to maintaining a large clinical practice and serving as Chief of the Retina Service at the Philadelphia VA Medical Center, Jeff was involved in collaborative research with investigators throughout the world. He had developed a system for evaluating digital fundus images which was applicable to patient care as well as to the evaluation of images from patients participating in randomized clinical trials. His extensive bibliography


included peer reviewed publications in the ophthalmic literature as well as the engineering literature. He was an expert on laser tissue interactions as well as optical imaging and retinal diseases. Among his more important recent publications were his principal editorship of the textbook entitled, Age-related Macular Degeneration published by C.V. Mosby in 1999, and a seminal review article on AMD which appeared in the "New England Journal of Medicine."

Enumerating publications and grants captures only one portion of the image that characterized Jeff. He was a loving husband to Karen and father of three children (Adina 11, Tamar 8, and Joseph 3), a pillar of his

synagogue and community in Cherry Hill, NJ, a valued and respected member of the faculty of Scheie Eye Institute at Penn, an inspiring teacher who had won the department's Golden Apple Award, and a consultant to several companies interested in the clinical applications of his research.

Jeff's friends and associates at Scheie, at Penn, and around the world are mourning our loss. With the passage of time, our pain will diminish and we will recall our wonderful interactions with Jeff. His contributions will continue to serve as a beacon that sheds light on the areas in which his insightful publications addressed unsolved problems in vision and ophthalmology.

*Jeff not only maintained a large clinical practice and served as Chief of the Retina Service at the Philadelphia VA Medical Center, but he was also involved in collaborative research with investigators throughout the world. His contributions will continue to serve as a beacon that sheds light on the areas in which his insightful publications addressed unsolved problems in vision and ophthalmology.*





# SCHEIE EYE INSTITUTE 127TH ANNIVERSARY MEETING PROGRAM

**FRIDAY, MAY 11, 2001**

**10 AM - 11:30 AM**  
**SEI Auditorium**

### **Retinal Degeneration**

Chairs: Jean Bennett, M.D., Ph.D. and Alan M. Laties, M.D.

Ann Milam, Ph.D. - *Concentric RP*

Artur Cideciyan, Ph.D. - *Visual cycle defect in fundus albipunctatus*

Tomas Aleman, M.D. - *Macular pigment in RP*

Jean Bennett, M.D., Ph.D. - *Gene therapy approaches for treatment of inherited retinal degeneration*

Albert Maguire, M.D. - *Gene therapy for an animal model of early onset retinal degeneration*

Samuel G. Jacobson, M.D., Ph.D. - *Progress towards treatment of Leber congenital amaurosis*

Eric Pierce, M.D., Ph.D. - *Progress toward understanding RP-1*

Joshua Dunaief, M.D., Ph.D. - *Apoptosis and oxidative stress in AMD*

**11:30 AM - 12:30 PM**  
**SEI Auditorium**

### **Cornea and Refractive Surgery and Oculoplastic Surgery**

Chairs: Roberta E. Gausas, M.D. and Stephen E. Orlin, M.D.

Stephen E. Orlin, M.D. - *Corneal melts and perforations*

Michael E. Sulewski, M.D. - *Complications of LASIK*

Alan Westeren, M.D. - *Mitomycin in PRK*

Raymond Douglas, M.D., Ph.D. - *Orbital posttransplantation lymphoproliferative disorder*

Scott Goldstein, M.D. - *Balloon dacryoplasty: from the lab to the patient*

Roberta E. Gausas, M.D. - *Management of periorbital squamous cell carcinoma: diagnostic and reconstructive issues*

**12:30 PM - 1:30 PM**  
**5th floor concourse**

Lunch

**1:30 PM - 3:00 PM**  
**SEI Auditorium**

### **Pediatric Ophthalmology and Oncology**

Chair: Monte Mills, M.D.

Monte Mills, M.D. - *Screening neonates for retinoblastoma*

Joan O'Brien, M.D. - *Management of retinoblastoma*

Terri Young, M.D. - *Refractive error genetics*

Graham Quinn, M.D. - *Treatment trial for ROP*

Joan O'Brien, M.D. - *Basic science questions in retinoblastoma*

Dan Gombos, M.D. - *Treating retinoblastoma when chemotherapy fails*

**3:00 PM - 3:30 PM**

Break

**3:30 PM - 5:00 PM**

### **Glaucoma**

Chair: Jody R. Piltz-Seymour, M.D.

Michael Kass, M.D. - *Ocular Hypertension Treatment Study*

Kenneth Shindler, M.D., Ph.D. - *Preventing retinal ganglion cell death*

Jody R. Piltz-Seymour, M.D. - *Contralateral effect of topical beta-blockers*

Michael Kass, M.D. - *Corneal thickness and IOP*

**7:00 PM - 10:00 PM**

Reception, dinner, and dancing at the Four Seasons Hotel, Philadelphia

# SCHEIE EYE INSTITUTE 127TH ANNIVERSARY MEETING PROGRAM

**SATURDAY, MAY 12, 2001**

**7:30 AM - 8:15 AM**

**Breakfast and Registration**

**8:15 AM - 9:45 AM**

**SEI Auditorium**

**Neuro-Ophthalmology**

Chair: Nicholas J. Volpe, M.D.

Neil Miller, M.D. - *Office diagnosis of myasthenia gravis*

Michael Lee, M.D. - *Visual field screening techniques*

Nicholas Volpe, M.D. - *Portable pupillography*

Laura Balcer, M.D. - *Visual dysfunction in multiple sclerosis*

Grant Liu, M.D. - *Neural correlate of Vernier Acuity: an event-related functional MRI study*

Neil Miller, M.D. - *Optic disc anomalies*

**9:45 AM - 10:15 AM**

**SEI Lobby**

Break

**10:15 AM - 11:00 AM**

**SEI Auditorium**

**Retina, Vitreous, and Macula**

Chair: Albert M. Maguire, M.D.

Jonathan Prenner, M.D. - *Risk factors for choroidal NV*

Stuart L. Fine, M.D. - *Prevention trials in AMD*

Lisa Schocket, M.D. - *Foveolar hemodynamics in proliferative DR*

Maureen Maguire, Ph.D. - *Results of AMD Thalidomide Trial*

Alexander J. Brucker, M.D. - *Juxtafoveal red spot*

**11:00 AM - 12:30 PM**

**SEI Auditorium**

**Adler Lecture and Public Health Ophthalmology**

Chair: Stuart L. Fine, M.D.

Melvin Rubin, M.D. - FRANCIS HEED ADLER LECTURE Depth perception and stereopsis

Evelina DiFranco - 4Sight Blindness Prevention Program

Harry Carrozza, M.D. - Ethics of managed care

Jeffrey Wick, M.D. - Visual function and graduated driving restrictions

Jane Loman - Dark exposure and myopia progression

**12:30 PM**

Adjournment

## INVITED GUEST SPEAKERS

**Melvin Rubin, M.D.**

Professor and Chair Emeritus, University of Florida

**Michael Kass, M.D.**

Professor and Chair, Washington University

**Neil Miller, M.D.**

Frank Walsh Professor, Johns Hopkins


**Joan O'Brien, M.D.**

Kimora Chair and Associate Professor, UCSF

# SCHEIE EYE INSTITUTE ALUMNI, FACULTY & GUESTS ENJOY ALUMNI RECEPTION HOTEL ADOLPHUS, DALLAS OCTOBER 23, 2000



Laura Fine, Ralph Shannon, Marc Alexandre, Lillian Lee, and Stephanie Phan.




Rich Lehrer and Rich Hertle.



Nancy Tsiaris, Michael Kresloff and Bill Tsiaris.



Gloriaman Hertle, Jill Foster, David Granet, Sara Louise Owens & Rich Hertle.




Marc Alexandre, Stuart and Ellie Fine.



Jay Smith and Allen Richmond.



Harvey & Roanna Brown.



Bill and Jill Trattler, Bruce Saran and Sandy Brucker.




Jane and Elliott Yolles.



Rob Stoltz, Kym Gendron, Scott Goldstein and Diane Chialant.



Barbara Hawkins, Steve Singer and Patricia Quinlan.



Charlie Nichols, Rich Kaiser and Jonathan Yoken.

Comments, suggestions?  
Please write, fax or e-mail to:

Ann Sacks  
Scheie Eye Institute  
51 North 39th Street  
Philadelphia, PA 19104

Phone: 215-662-8774  
Fax: 215-662-0462  
Email: ann.sacks@uphs.upenn.edu

[www.med.upenn.edu/opth/](http://www.med.upenn.edu/opth/)

## LECTURES AND SEMINARS

### FEBRUARY 2000 – JUNE 2001

**Visiting Scientist Lectures are scheduled on Thursdays from 7:45-8:30 AM in the Scheie Eye Institute Auditorium followed by a lunch seminar Noon-1:00 PM in the 5th fl Conference Room.**

**FEBRUARY 1**  
**John Flannery, Ph.D.**  
School of Optometry  
University of California at Berkeley  
**7:45 AM** *Gene therapy for retinal diseases*  
**Noon** *Adeno-associated viral-mediated gene therapy for retinal diseases*

**FEBRUARY 8**  
**Richard A. Stone, M.D.**  
Scheie Eye Institute  
**7:45 AM** *Myopia and the Daily Light: Dark Cycle*

**Artur V. Cideciyan, Ph.D.**  
Scheie Eye Institute  
**Noon** *Functional reserve at the first synapse of the visual system*

**FEBRUARY 10**  
CME program: Management Decisions in Glaucoma, 2001  
**Dale Heuer, M.D.**  
Professor and Chair, Department of Ophthalmology  
Medical College of Wisconsin

**FEBRUARY 15**  
**Alan M. Laties, M.D.**  
Scheie Eye Institute  
**Noon** *How photoreceptors survive*

**FEBRUARY 22**  
**Michael Tolentino, M.D.**  
Scheie Eye Institute

**7:45 AM** *Growth factors and inhibitors in ocular neovascularization*  
**Gerard A. Lutty, Ph.D.**  
The Wilmer Institute/Johns Hopkins  
**Noon** *Animal models of sickle cell disease*

**MARCH 8**  
**James P. Dunn, M.D.**  
The Wilmer Institute/Johns Hopkins  
**7:45 AM** *Intravitreal drug delivery*  
**Noon** *Phenotypic and genotypic mutations in patients with CMV retinitis*

**MARCH 22**  
**James M. Tielsch, Ph.D.**  
Department of International Health  
Johns Hopkins School of Hygiene and Public Health

**7:45 AM** *Cataract outcomes research: progress or old news?*  
**Noon** *What's new in the epidemiology of glaucoma: incidence to screening*

**MARCH 29**  
**Carol M. Mangione, M.D.**  
UCLA School of Medicine  
Los Angeles, California

**7:45 AM** *Outcomes after Cataract Surgery and Intraocular Lens Implantation*

**Noon** *Measuring Responsiveness of the 25-item NEI-VFQ*

**APRIL 12**  
**Harry A. Quigley, M.D.**  
The Wilmer Institute/Johns Hopkins  
**7:45 AM** *Changing our approach to glaucoma as we understand it better*  
**Noon** *Glaucoma from macrocosm to microcosm*

**APRIL 19**  
**Ronald Klein, M.D., M.P.H.**  
University of Wisconsin, Madison  
**7:45 AM** *An evidence-based approach to the management and prevention of age-related macular degeneration*

**Noon** *Twenty-years of observations from the field: the Wisconsin epidemiological study of diabetic retinopathy*

**MAY 4**  
**Professor Dr. Med. Ursula Schmidt-Erfurth**  
University of Luebeck, Germany  
**7:45 AM** *Photodynamic Therapy (PDT) in Age-related Macular Degeneration*

**Noon** *Mechanism of Action of Photodynamic Therapy*

**MAY 10**  
**Robert D. Reinecke, M.D.**  
Wills Eye Hospital/Thomas Jefferson University

**7:45 AM** *Strabismus and its treatment in the presence of nystagmus*

**Noon** *Natural history of nystagmus in young children*

**CME: SEI 127TH ANNIVERSARY MEETING - SEE INSERT FOR DETAILS**

**MAY 24**  
**Hans E. Grossniklaus, M.D.**  
Emory University Eye Center  
Atlanta, Georgia  
**7:45 AM** *Metastatic uveal melanoma. Clinical, pathologic and experimental findings*  
**Noon** *Age-related macular degeneration. Clinical, pathologic and experimental findings*

**JUNE 7**  
**Sharon Fekrat, M.D.**  
Duke University Eye Center  
Durham, North Carolina  
**7:45 AM** *Vitreous surgery for branch vein occlusion: the CUTS trial*  
**Noon** *Role of the vitreous in venous occlusive disease*

**JUNE 14**  
**James P. Gills, M.D.**  
St. Luke's Eye Center  
Tarpan Springs, Florida  
**7:45 AM** *Advances in Anterior Segment Surgery, Part 1*  
**Noon** *Advances in Anterior Segment Surgery, Part 2*

**For more information on lectures and seminars,  
call Sue Hess at 215-662-8020 or e-mail to [sueh@mail.med.upenn.edu](mailto:sueh@mail.med.upenn.edu)**